

## Revised Draft Agenda

### Biocides Working Group Meeting II-2022 30 May – 10 June 2022

Remote participation: Virtual meeting using WebEx  
Physical participation: ECHA Conference Centre (Telakkakatu 6)

Coffee break 10:30/11:00-11:30  
Lunch break 12:30/13:00-14:00  
Coffee break 15:00/16:00-15:30/16:30

The time is indicated in Helsinki time.

Tuesday 7 June	09:30-18:00	APCP WG – physical (Meeting room Sampo BC)
Wednesday 8 June	09:30-18:00	APCP WG – physical (Meeting room Sampo BC)
Thursday 9 June	09:30-18:00	APCP WG – physical (Meeting room Sampo BC)
Friday 10 June	09:00-13:00	APCP WG – physical (Meeting room Sampo BC)
Tuesday 31 May	09:30-18:00	TOX WG – physical (Meeting room Urho)
Wednesday 1 June	09:30-18:00	TOX WG – physical (Meeting room Urho)
Thursday 2 June	09:30-18:00	TOX WG – physical (Meeting room Urho)
Friday 10 June	10:00-18:00	TOX WG - virtual
Tuesday 31 May	10:00-16:00	EFF WG – physical (Meeting room Sampo A)
Wednesday 1 June	10:00-18:00	EFF WG – physical (Meeting room Sampo A)
Thursday 2 June	10:00-16:00	EFF WG – physical (Meeting room Sampo A)
Monday 30 May	09:30-18:00	ENV WG - virtual
Wednesday 8 June	09:30-18:00	ENV WG – physical (Meeting room Voima)
Thursday 9 June	09:30-18:00	ENV WG – physical (Meeting room Voima)

Friday 10 June	09:00-15:00	ENV WG – physical (Meeting room Voima)
Thursday 16 June	09:30-18:00	ENV WG/AHEE – virtual

<b>Analytical methods and physico-chemical properties            Working Group</b>  <b>Chair: Bernhard Krebs</b>		
<b>Item 1 - Welcome and apologies</b>		
<b>Item 2 – Administrative issues</b>		
<b>Item 3 – Agreement of the agenda</b>		
<i>For agreement</i>		
<b>Item 4 – Declarations of potential conflicts of interest in relation to the agenda</b>		
<b>Item 5 – Agreement on the minutes of WG I 2022</b>		
<i>For agreement</i>		
<b>Item 6 – Outcome of e-consultations (closed session)</b>		
<b>Item 7 – Technical and guidance related items</b>		
<b>7.1.</b>	<b>Waiving justifications for physical hazards (closed session)</b> <i>For discussion</i>	
<b>7.2</b>	<b>Unstable active substances (closed session)</b> <i>For discussion</i>	
<b>7.3</b>	<b>Technical Agreements Biocides (TAB)</b> <i>For agreement</i>	
<b>7.4</b>	<b>Biocidal products - in situ active substances – case type 3</b> <i>For discussion</i>	NL
<b>Item 8 - Discussion on Active Substances</b>		
<b>8.1</b>	<b>Mecetronium ethyl sulphate (MES)</b> PT01 Meeting document: WG II 2022_APCP_8-1 <i>For agreement</i>	PL
<b>8.2</b>	<b>Ozone generated from oxygen</b> PT02, 04, 05, 11 Meeting document: WG II 2022_APCP_8-2 <i>For agreement</i>	NL

<b>Item 9 - Discussions on Union Authorisations</b>		<b>eCA</b>
<b>9.1</b>	<b>UA for a product family containing peracetic acid</b> PT02, 03,04 (BC-QN034236-29) Meeting document: WG II 2022_APCP_9-1 <i>For agreement</i>	DE
<b>9.2</b>	<b>UA for a product family containing hydrogen peroxide</b> PT02, 03, 04 (BC-HC029658-43) Meeting document: WG II 2022_APCP_9-2 <i>For agreement</i>	NL
<b>9.3</b>	<b>UA for a product family containing active chlorine released from sodium hypochlorite</b> PT 02, 03, 04, 05 (BC-HQ045419-21) Meeting document: WG II 2022_APCP_9-3 <i>For agreement</i>	FR
<b>9.4</b>	<b>UA for a product family containing active chlorine released from sodium hypochlorite</b> PT 02, 03, 04, 05 (BC-LK045398-25) Meeting document: WG II 2022_APCP_9-4 <i>For agreement</i>	FR
<b>Item 10 – AoB</b>		

Human Health Working Group		
Chair: Antero Airaksinen		
<b>Item 1 - Welcome and apologies</b>		
<b>Item 2 – Administrative issues</b>		
<b>Item 3 – Agreement of the agenda</b>		
<i>For agreement</i>		
<b>Item 4 – Declarations of potential conflicts of interest in relation to the agenda</b>		
<b>Item 5 – Agreement on the minutes of WG I 2022</b>		
<i>For agreement</i>		
<b>Item 6 - Discussion on Active Substances</b>		<b>eCA</b>
<b>6.1.</b>	<b>Ozone generated from oxygen</b> PT02, 04 05, 11 Meeting document: WG II 2022_TOX_6-1 <div style="text-align: right;"><i>For agreement</i></div>	NL
<b>6.2</b>	<b>Mecetronium ethyl sulphate (MES)</b> PT01 Meeting document: WG II 2022_TOX_6-2 <div style="text-align: right;"><i>For agreement</i></div>	PL
<b>6.3</b>	<b>Early review: Iodine, PVP-iodine - ED Assessment</b> Meeting document: WG II 2022_TOX_6-3 <div style="text-align: right;"><i>For agreement</i></div>	SE
<b>6.4</b>	<b>Early WG: Margosa extract from cold-pressed oil of the kernels of Azadirachta Indica extracted with super-critical carbon dioxide</b> PT18 Meeting document: WG II 2022_TOX_6-4 <div style="text-align: right;"><i>For agreement</i></div>	DE
<b>6.5</b>	<b>Early WG: In situ generated monochloramines</b> Meeting document: WG II 2022_TOX_6-5 <div style="text-align: right;"><i>For agreement</i></div>	
<b>6.6</b>	<b>Sorbic acid</b> PT06 Meeting document: WG II 2022_TOX_6-6 <div style="text-align: right;"><i>For agreement</i></div>	DE
<b>6.7</b>	<b>Sulphur dioxide generated from sulphur by combustion</b> PT04 Meeting documents: WG II 2022_TOX_6-7 <div style="text-align: right;"><i>For agreement</i></div>	DE
<b>6.8</b>	<b>Sulfur dioxide released from sodium metabisulfite</b> PT09 Meeting documents: WG II 2022_TOX_6-8 <div style="text-align: right;"><i>For agreement</i></div>	DE

<b>Item 7 - Discussions on Union Authorisations</b>		<b>eCA</b>
<b>7.1</b>	<b>UA for a product family containing hydrogen peroxide</b> PT02-04 (BC-HC029658-43) Meeting document: WG II 2022_TOX_7-1 <i>For agreement</i>	NL
<b>7.2</b>	<b>UA for a product family containing active chlorine released from sodium hypochlorite</b> PT 02-05 (BC-HQ045419-21) Meeting document: WG II 2022_TOX_7-2 <i>For agreement</i>	FR
<b>7.3</b>	<b>UA for a product family containing active chlorine released from sodium hypochlorite</b> PT02-04 (BC-LK045398-25) Meeting document: WG II 2022_TOX_7-3 <i>For agreement</i>	FR
<b>7.4</b>	<b>UA for a product family containing peracetic acid</b> PT03-04 (BC-QN034236-29) Meeting document: WG II 2022_TOX_7-4 <i>For agreement</i>	DE
<b>Item 8 – AoB</b>		<b>Presenter</b>
<b>8.1</b>	<b>Other information</b> Meeting document: WG II 2022_TOX_8-1 <i>For discussion</i>	SECR

Environment Working Group		
Chair: Heike Schimmelpfennig		
<b>Item 1 - Welcome and apologies</b>		
<b>Item 2 – Administrative issues</b>		
<b>Item 3 – Agreement of the agenda</b>		
<i>For agreement</i>		
<b>Item 4 – Declarations of potential conflicts of interest in relation to the agenda</b>		
<b>Item 5 – Agreement of the minutes of WG-I-2022</b>		
<i>For agreement</i>		
Item 6 - Discussion on Active Substances		eCA
<b>6.1</b>	<b>Ozone generated from oxygen</b> PT02, 04 05, 11 Meeting document: WGII2022_ENV_6-1 <div style="text-align: right;"><i>For agreement</i></div>	NL
<b>6.2</b>	<b>Mecetronium ethyl sulphate (MES)</b> PT01 Meeting document: WGII2022_ENV_6-2 <div style="text-align: right;"><i>For agreement</i></div>	PL
<b>6.3</b>	<b>Early review: Iodine, PVP-iodine - ED Assessment</b> Meeting document: WGII2022_ENV_6-3 <div style="text-align: right;"><i>For agreement</i></div>	SE
Item 7 - Discussions on Union Authorisations		eCA
<b>7.1</b>	<b>UA for a product family containing hydrogen peroxide</b> PT02-04 (BC-HC029658-43) Meeting document: WGII2022_ENV_7-1 <div style="text-align: right;"><i>For agreement</i></div>	NL
<b>7.2</b>	<b>UA for a product family containing active chlorine released from sodium hypochlorite</b> PT 02-05 (BC-HQ045419-21) Meeting document: WGII2022_ENV_7-2 <div style="text-align: right;"><i>For agreement</i></div>	FR
<b>7.3</b>	<b>UA for a product family containing active chlorine released from sodium hypochlorite</b> PT02-04 (BC-LK045398-25) Meeting document: WGII2022_ENV_7-3 <div style="text-align: right;"><i>For agreement</i></div>	FR
<b>7.4</b>	<b>UA for a product family containing peracetic acid</b> PT03-04 (BC-QN034236-29) Meeting document: WGII2022_ENV_7-4 <div style="text-align: right;"><i>For agreement</i></div>	DE

<b>Item 8 – Technical and guidance related issues</b>		<b>Presenter</b>
<b>8.1</b>	<b>Draft revision of in-situ ENV recommendations – for information (closed session)</b> Meeting document: WGII2022_ENV_8-1 <i>For information/discussion</i>	SECR
<b>8.2</b>	<b>Infobox 12, choice of the assessment factor when plants are as sensitive as other organisms</b> Meeting document: WGII2022_ENV_8-2 <i>For agreement</i>	FR
<b>8.3</b>	<b>Outcome EG meeting on fate and distribution models</b> Meeting document: WGII2022_ENV_8-3 <i>For agreement</i>	SECR
<b>8.4</b>	<b>Follow up AHEE-6 Item 4.4: PT 18 -- Outdoor large-scale spraying</b> Meeting document: WGII2022_ENV_8-4 <i>For agreement</i>	SECR
<b>8.5</b>	<b>PT 18 Emission scenario (CEFIC)</b> Meeting document: WGII2022_ENV_8-5 <i>For agreement</i>	CEFIC
<b>8.6</b>	<b>Manure and slurry storage – selection of European standard temperatures</b> Meeting document: WGII2022_ENV_8-6 <i>For agreement</i>	DE/NL
<b>Item 9 – AoB</b>		<b>Presenter</b>
<b>9.1</b>	<b>Other information</b> Meeting document: WGII2022_ENV_9-1 <i>For information</i>	ECHA
<b>9.2</b>	<b>Update on Chesar platform developments</b> Meeting document: WGII2022_ENV_9-2 <i>For information</i>	ECHA



Efficacy Working Group		
Chair: Kasia Szymankiewicz		
<b>Item 1 - Welcome and apologies</b>		
<b>Item 2 – Administrative issues</b>		
<b>Item 3 – Agreement of the agenda</b>		
<i>For agreement</i>		
<b>Item 4 – Declarations of potential conflicts of interest in relation to the agenda</b>		
<b>Item 5 – Agreement on the minutes of WG I 2022</b>		
<i>For agreement</i>		
<b>Item 6 - Discussion on Active Substances</b>		<b>eCA</b>
<b>6.1.</b>	<b>Ozone generated from oxygen</b> PT02, 04 05, 11 Meeting document: WG II 2022_EFF_6-1  <div style="text-align: right;"><i>For agreement</i></div>	NL
<b>6.2</b>	<b>Mecetronium ethyl sulphate (MES)</b> PT01 Meeting document: WG II 2022_EFF_6-2  <div style="text-align: right;"><i>For agreement</i></div>	PL
<b>Item 7 - Discussions on Union Authorisations</b>		<b>eCA</b>
<b>7.1</b>	<b>UA for a product family containing hydrogen peroxide</b> PT02-04 (BC-HC029658-43) Meeting document: WG II 2022_EFF_7-1  <div style="text-align: right;"><i>For agreement</i></div>	NL
<b>7.2</b>	<b>UA for a product family containing active chlorine released from sodium hypochlorite</b> PT 02-05 (BC-HQ045419-21) Meeting document: WG II 2022_EFF_7-2  <div style="text-align: right;"><i>For agreement</i></div>	FR
<b>7.3</b>	<b>UA for a product family containing active chlorine released from sodium hypochlorite</b> PT02-04 (BC-LK045398-25) Meeting document: WG II 2022_EFF_7-3  <div style="text-align: right;"><i>For agreement</i></div>	FR
<b>7.4</b>	<b>UA for a product family containing peracetic acid</b> PT03-04 (BC-QN034236-29) Meeting document: WG II 2022_EFF_7-4  <div style="text-align: right;"><i>For agreement</i></div>	DE

<b>Item 8 – Technical and guidance related issues</b>		<b>Presenter</b>
<b>8.1</b>	Antimicrobial resistance - draft guidance Meeting document: WGII2022_EFF_8-1 <i>For discussion</i>	FR
<b>8.2</b>	Differentiation of virucidal claim in PT4 (hard surface disinfection) Meeting document: WGII2022_EFF_8-2 <i>For discussion</i>	FR
<b>8.3</b>	Influence of wipe/mop materials on the efficacy of surface disinfection products Meeting document: WGII2022_EFF_8-3 <i>For discussion</i>	DE
<b>Item 9 – AoB</b>		<b>Presenter</b>
<b>9.1</b>	Other info	ECHA